Poseida Therapeutics Inc. may have one of the first BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapies approved in the US for multiple myeloma, which is why investors were eager to invest in the initial public offering the company proposed in January. But when the IPO was waylaid by the US government shutdown, other options for funding its development programs emerged.
Poseida's CAR-T, Gene Therapy Programs Get $142m Boost, Including Novartis Cash
Despite its sidetracked IPO, a registrational trial for the company's BCMA-targeting CAR-T is underway to support a late 2020 BLA filing and this new VC funding could accelerate additional programs. CAR-T pioneer Novartis is strictly an investor in the Series C round, but takes a board seat.
More from Financing
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.